Merck to Fire 8,500 in Strategy Overhaul That Shifts R&D

Merck & Co., the second-biggest U.S. drugmaker by sales, will fire 8,500 workers and revamp its research and development after seeing new medicines delayed by U.S. regulators.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.